The concentration of new and doubled positions from high-conviction active funds (Point72, Citadel, Two Sigma) signals strong institutional belief in near-term catalysts. Monitor for atacicept Phase 3 data or regulatory updates. The Morgan Stanley exit is a cautionary signal but appears idiosyncratic given the broad buying.
Executive Summary
Seven institutional investors accumulated $115.7M in VERA during Q3 2025, led by Point72's new $37M position and Citadel's doubling to $46.9M, while Morgan Stanley nearly exited its $52.7M stake. The cluster is dominated by active quant and asset-manager buyers, suggesting a shared thesis around Vera's pipeline catalysts (likely atacicept in IgA nephropathy) outweighing the risk-off signal from Morgan Stanley's exit.
Key Financial Metrics
Institutional Positions
Net institutional flow: $44.0M
▲ Buyers (7)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Point72 | NEW | — | $37.0M | $37.0M |
| Citadel | DOUBLED | +187% | $46.9M | $33.7M |
| Dimensional Fund Advisors | DOUBLED | +134.5% | $10.5M | $6.9M |
| Nuveen | DOUBLED | +191.5% | $9.2M | $6.7M |
| Two Sigma | ADD | +32.9% | $5.0M | $1.9M |
| UBS | ADD | +57.5% | $4.7M | $2.3M |
| Wells Fargo | DOUBLED | +140% | $2.4M | $1.6M |
▼ Sellers (2)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | NEAR_EXIT | -87.7% | $52.7M | -$44.8M |
| Ubs Am, A Distinct Business Un | TRIM | -46.3% | $3.6M | -$1.2M |
Key Facts
- 7 buyers accumulated $90.0M net; 2 sellers reduced by $46.0M
- Point72 initiated a new $37.0M position (1.27M shares)
- Citadel doubled its stake to $46.9M (+$33.7M)
- Morgan Stanley cut 87.7% of its position, exiting $44.8M
- Active managers (Point72, Citadel, Two Sigma) drove 80% of buying value
- Passive rebalancing by Wells Fargo and UBS added modest $3.9M combined
Financial Impact
Net institutional buying of $44.0M (7 buyers added $90.0M, 2 sellers removed $46.0M) represents ~1.9% of VERA's $2.3B market cap
Risk Factors
- 13F data is 45+ days stale; positions may have been unwound
- Morgan Stanley's near-exit could reflect material non-public concerns
- Biotech binary catalyst risk — any pipeline setback would reverse the thesis
- Historical VERA reports show negative T+20 alpha (-4.89% vs SPY) despite 70% win rate
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-VERA-2025-Q3 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $33.67 $34.00 | ▲ +0.98% | ▲ +0.16% | — |
Aug 10, 2026 7w ago | 8-K | $30.29 $32.28 | ▲ +6.57% | ▲ +6.97% | — |
Aug 10, 2026 7w ago | Press Release | $30.29 $32.28 | ▲ +6.57% | ▲ +6.97% | — |
Jul 9, 2026 12w ago | 8-K | $42.45 $39.12 | ▼ −7.84% | ▼ −7.71% | — |
Jul 7, 2026 12w ago | 8-K | $42.96 $43.13 | ▲ +0.40% | ▼ −0.16% | — |
Jun 11, 2026 16w ago | Institutional Cluster | $33.65 $35.01 | ▲ +4.04% | ▲ +3.61% | — |
Jun 2, 2026 17w ago | 8-K | $31.26 $31.81 | ▲ +1.76% | ▲ +4.72% | — |
Jun 2, 2026 17w ago | Press Release | $31.26 $31.81 | ▲ +1.76% | ▲ +4.72% | — |
May 7, 2026 21w ago | 8-K | $35.88 $39.15 | ▲ +9.11% | ▲ +7.61% | — |
Feb 26, 2026 31w ago | 8-K | $42.35 $38.85 | ▼ −8.26% | ▼ −7.14% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access